A Phase 1 trial of the anti-CD27 antibody administered alone and in combination with pembrolizumab in adults with advanced solid tumors

Trial Profile

A Phase 1 trial of the anti-CD27 antibody administered alone and in combination with pembrolizumab in adults with advanced solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Anti-CD27-antibody (Primary) ; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Mar 2018 New trial record
    • 05 Mar 2018 According to an Aduro Biotech media release, the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase I clinical trial of its anti-CD27 antibody.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top